Abstract
Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Keywords: Regulatory T cells, tumor immunology, FOXP3
Current Pharmaceutical Design
Title: Regulatory T Cells: Major Players in the Tumor Microenvironment
Volume: 15 Issue: 16
Author(s): Marc Beyer and Joachim L. Schultze
Affiliation:
Keywords: Regulatory T cells, tumor immunology, FOXP3
Abstract: Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Export Options
About this article
Cite this article as:
Beyer Marc and Schultze L. Joachim, Regulatory T Cells: Major Players in the Tumor Microenvironment, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453211
DOI https://dx.doi.org/10.2174/138161209788453211 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Small-Molecule Inhibitors Targeting eIF4A in Leukemia
Current Protein & Peptide Science New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications
Current Radiopharmaceuticals Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Antivenoms for Snakebite: Design, Function, and Controversies
Current Pharmaceutical Biotechnology Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Current Gene Therapy Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Characterization of MHC Ligands for Peptide Based Tumor Vaccination
Current Pharmaceutical Design Diagnostic Methods in the Detection of Prostate Cancer: Prospective Observational Study
Current Medical Imaging Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer
Current Genomics Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Dequalinium-Derived Nanoconstructs: A Promising Vehicle for Mitochondrial Targeting
Current Drug Delivery Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews